Anavex says FDA grants meeting request on adding pediatric patients to Phase 3 Rett syndrome trial of blarcamesine
AVXL•FDA meeting request on Rett syndrome trial expansion
Anavex says FDA granted a meeting to discuss adding pediatric patients to its Phase 3 Rett syndrome trial of ANAVEX 2-73.
No clinical results were presented, with the update focused on potential trial expansion rather than study outcomes.
The move could broaden the addressable patient population, supporting the strategic push behind the Rett syndrome program.
